Combination therapy for prostate cancer
PH12019502317B1Active Publication Date: 2026-07-31JANSSEN PHARMA NV
0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- PH · PH
- Patent Type
- Patents
- Current Assignee / Owner
- JANSSEN PHARMA NV
- Filing Date
- 2019-10-10
- Publication Date
- 2026-07-31
Abstract
Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.
Need to check novelty before this filing date? Find Prior Art